This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

Pharmacological treatment of attention-deficit/hyperactivity disorder in adults with severe substance use disorder is associated with lower mortality: A Swedish register-based study

Medication of attention deficit hyperactivity disorder in adults with severe substance use disorder is associated with reduced mortality: a swedish register-based study

Among adults with co-occurring ADHD and severe substance use disorder, central nervous system stimulant prescribing was associated with a markedly lower one-year mortality rate.

The study aimed to examine the association between central nervous system stimulant treatment and mortality among individuals diagnosed with both attention-deficit/hyperactivity disorder (ADHD) and severe substance use disorder (SUD). In this study based on Swedish national registers, patients aged 18 years and older who were discharged from compulsory addiction care between July 1, 2005, and December 31, 2020, were identified through the Swedish National Register of Care for Substance Abuse, and those who received an ICD-10 diagnosis of ADHD by the end of follow-up were included in the cohort; because this register includes individuals admitted to compulsory care for severe substance use, it was used as a proxy measure for severe SUD. The date and cause of death were determined by linkage to the Swedish Cause of Death Register, and the mortality rate was estimated using a Cox proportional hazards regression model. The cohort consisted of 1,897 individuals. The one-year mortality rate was 76.5% lower among those receiving treatment than among those not receiving treatment (95% confidence interval [CI] 63.8–84.8; hazard ratio [HR] = 0.24; p<0.0001); a multivariable analysis of one-year survival also found significantly lower mortality among those receiving treatment (95% CI 0.148–0.354; HR 0.229; p<0.0001). The authors report that the protective effect was greatest in individuals receiving full treatment and gradually diminished after treatment was discontinued.

All WCP 2026 summaries